The insider selling cluster is too small in dollar terms and involves only directors, not C-suite executives, to warrant a bearish read. Monitor for any C-suite open-market sales or a material increase in selling volume before adjusting positioning.
WVE drugs
WVE drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Aug 14 $5.41entry
- T+1 · 3mo ago −5.92%α −5.44% · $5.09
- T+5 · 3mo ago −2.22%α −0.85% · $5.29
- T+20 · 2mo ago −15.34%α −13.35% · $4.58
- T+60 · 8d ago −35.67%α −32.63% · $3.48
Price Chart
How similar events traded
Executive Summary
Three Wave Life Sciences directors sold a total of ~$132K in open-market shares over a one-week window, with the largest sale ($67K) occurring on August 12 at $5.29. The cluster is small relative to the $1.0B market cap (~0.013%), and all sellers are non-C-suite directors, which per the academic literature carries weak predictive power for insider sales.
Key Financial Metrics
Key Facts
- Three directors sold a combined ~$132K in open-market shares from Aug 5-12, 2026
- Largest sale: Director Adrian Rawcliffe sold 12,700 shares at $5.29 for $67,183
- Heidi L. Wagner exercised 7,000 derivative shares (non-cash) and simultaneously sold 7,000 shares at $6.01
- Total cluster value of $132K represents ~0.013% of WVE's $1.0B market cap
- No C-suite executives (CEO, CFO, COO) participated in any trades
Financial Impact
$132K in total insider sales, ~0.013% of market cap, immaterial
Risk Factors
- Director sales could precede a broader insider selling trend if C-suite executives follow
- No positive catalyst identified to offset the selling signal
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-WVE-1786669361850 |
Track record
16 reports on WVE
3 of 4 bullish or bearish reports moved the stock their way by T+1. Best: +17.42% at T+5 after the Mar 26, 2026 report. 3 of 4 went positive at some point.
Filters
- Nov 13, 20263d ago Press Release Neutral 4/10 Entry $3.13 to $2.87 Now $2.87 −8.31% ▼ −8.31% −6.40% vs SPY
- Oct 27, 202620d ago SC 13G Neutral 4/10 Entry $3.64 to $3.63 Now $2.87 −21.15% ▼ −0.27% +0.11% vs SPY
- Oct 27, 202620d ago SC 13G/A Neutral 2/10 Entry $3.45 to $3.64 Now $2.87 −16.81% ▲ +5.51% +5.16% vs SPY
- Oct 27, 202620d ago 8-K Bullish 6/10 No price data
- Oct 27, 202620d ago Press Release Neutral 5/10 Entry $3.45 to $3.64 Now $2.87 −16.81% ▲ +5.51% +5.16% vs SPY
- Oct 14, 20264w ago DEF 14A Neutral 4/10 Entry $3.19 to $3.13 Now $2.87 −10.03% ▼ −1.88% −0.77% vs SPY
- Sep 30, 20266w ago Press Release Bullish 5/10 Entry $3.70 to $3.88 Now $2.87 −22.43% ▲ +4.86% +4.69% vs SPY
- Aug 13, 202613w ago Insider Cluster Neutral 3/10 Viewing Entry $5.41 to $5.09 Now $2.87 −46.95% ▼ −5.92% −5.44% vs SPY
- May 18, 202626w ago Press Release Bullish 7/10 Entry $6.14 to $6.19 Now $2.87 −53.26% ▲ +0.81% −0.23% vs SPY
- Apr 28, 202628w ago 8-K Bullish 7/10 No price data
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers